Sevirumab
Alternative Names: EV2 7; MSL 109; Protovir; SDZ MSL 109Latest Information Update: 22 Jul 2016
At a glance
- Originator Novartis
- Developer Novartis; PDL BioPharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 22 Jul 2016 Changed the NDR date to 2007 because NCT00002016 was completed in 2005
- 23 Jun 2007 No-Development-Reported for Cytomegalovirus infections in USA (IV) (NCT00002016)
- 17 May 2001 No-Development-Reported for Cytomegalovirus infections in Switzerland (IV)